Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Survival Rate”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed1982

[Interdependence of response rates, survival rates, stage and histology after radio-/chemotherapy in patients with advanced ovarian carcinoma].

Between February 1977 and February 1981, 55 patients with ovarian cancer (45 at stage III and 10 at stage IV) underwent simultaneous radio-/chemotherapy and early therapeutic second-look operation. The overall response rate amounts to 94%, 63% of which are complete and 31% are partial remissions. Stage III comprises 74% complete and 26% partial remissions. Patients with complete remission at stage III have a significantly longer tumor-free survival time than patients with partial remission (median 16 vs. 8 months). A longer overall survival time (median 30 vs. 16 months) is also significant. At stage III there have been 74% successful therapeutic second operations. In all patients with residual tumors above 2 cm in diameter after primary operation a response rate of 92% could be achieved, 52% showed complete remissions. The survival time proved to be independent of both histological parameter and age. The remaining residual tumor above or under 2 cm in diameter in any single location is, however, a significant prognostic factor for long-time survival. Possible curative chances for patients with stage III disease are only to be expected through interdisciplinary oncological cooperation.

Adult↗
PubMed1991

Numerators, denominators, and survival rates: reporting survival from out-of-hospital cardiac arrest.

This study demonstrates the effect of different denominators on the survival rate from out-of-hospital cardiac arrest. We retrospectively analyzed data from a cardiac arrest surveillance system in King County, Washington during the years 1976 to 1988, and calculated survival rates using eight different definitions of denominators. The eight survival rates ranged from 16% to 49% discharge from hospital. The denominator for the lowest survival rate included all cases of cardiac arrest for whom emergency medical services personnel started cardiopulmonary resuscitation. The denominator for the highest survival rate included: all cases of presumed cardiac etiology; first recorded rhythm was ventricular fibrillation; collapse witnessed; cardiopulmonary resuscitation started by bystanders within 4 minutes; and definitive care provided within 8 minutes. The definition of cases included in the denominator can dramatically effect the resultant survival rate. There must be national and international agreement about definitions of denominators for valid cross community comparisons.

Emergencies↗
PubMed1980

[Comparison between surgical and conservative treatment (106Ru/106Rh beta rays) of choroidal melanoma calculated by survival rate and survival time using the life table method (author's transl)].

According to the literature about 40 to 50 percent of patients with malignant melanoma of the choroid die of metastases within five years of enucleation. These figures justify the search for more effective methods and treatment. Computation of the survival rate using the life table method commonly applied in demographic studies is explained, and described by reference to the practical example of a comparison of two patient collectives. Out of 214 patients treated by enucleation, 67.6% were still alive five years later, while 90.7% of 136 patients treated with 106Ru/106Rh applicators survived the same period of time.

Choroid Neoplasms↗
PubMed2004

Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias.

Implantable cardioverter defibrillators (ICDs) have improved survival for patients with ventricular fibrillation (VF) or sustained vertricular tachycardia (VT). However, the survival of these patients compared to the general population has not been assessed. Observed survival rates for patients randomized to either antiarrhythmic drug therapy (mainly amiodarone) arm or ICD arm were compared to expected rates, calculated using age and sex-specific survival rates derived from the 1989-1991 US population life tables and applied to the age and sex distribution of patients in each arm. Consistent with the results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, patients randomized to receive ICDs experienced significantly higher survival than those in the drug arm; however, both groups experienced significantly lower survival than expected using age and gender matched U.S. survival rates. Within arms, the difference between the observed and expected rates increased over 3 years of follow-up from 7.7% to 15.3% for the ICD arm, and from 14.6% to 26.4% for the drug arm. These results quantify the improvements in survival that can be expected for VF or VT patients using drug or ICD therapies and underscore the need for continued research into methods for further improving the overall level of health of these patients.

Aged↗
PubMed2005

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.

Published data on prognostic and predictive factors in patients with gliomas are largely based on clinical trials and hospital-based studies. This review summarizes data on incidence rates, survival, and genetic alterations from population-based studies of astrocytic and oligodendrogliomas that were carried out in the Canton of Zurich, Switzerland (approximately 1.16 million inhabitants). A total of 987 cases were diagnosed between 1980 and 1994 and patients were followed up at least until 1999. While survival rates for pilocytic astrocytomas were excellent (96% at 10 years), the prognosis of diffusely infiltrating gliomas was poorer, with median survival times (MST) of 5.6 years for low-grade astrocytoma WHO grade II, 1.6 years for anaplastic astrocytoma grade III, and 0.4 years for glioblastoma. For oligodendrogliomas the MSTwas 11.6 years for grade II and 3.5 years for grade III. TP53 mutations were most frequent in gemistocytic astrocytomas (88%), followed by fibrillary astrocytomas (53%) and oligoastrocytomas (44%), but infrequent (13%) in oligodendrogliomas. LOH 1p/19q typically occurred in tumors without TP53 mutations and were most frequent in oligodendrogliomas (69%), followed by oligoastrocytomas (45%), but were rare in fibrillary astrocytomas (7%) and absent in gemistocytic astrocytomas. Glioblastomas were most frequent (3.55 cases per 100,000 persons per year) adjusted to the European Standard Population, amounting to 69% of total incident cases. Observed survival rates were 42.4% at 6 months, 17.7% at one year, and 3.3% at 2 years. For all age groups, survival was inversely correlated with age, ranging from an MST of 8.8 months (<50 years) to 1.6 months (>80 years). In glioblastomas, LOH 10q was the most frequent genetic alteration (69%), followed by EGFR amplification (34%), TP53 mutations (31%), p16INK4a deletion (31%), and PTEN mutations (24%). LOH 10q occurred in association with any of the other genetic alterations, and was the only alteration associated with shorter survival of glioblastoma patients. Primary (de novo) glioblastomas prevailed (95%), while secondary glioblastomas that progressed from low-grade or anaplastic gliomas were rare (5%). Secondary glioblastomas were characterized by frequent LOH 10q (63%) and TP53 mutations (65%). Of the TP53 mutations in secondary glioblastomas, 57% were in hot-spot codons 248 and 273, while in primary glioblastomas, mutations were more evenly distributed. G:C-->A:T mutations at CpG sites were more frequent in secondary than primary glioblastomas, suggesting that the acquisition of TP53 mutations in these glioblastoma subtypes may occur through different mechanisms.

Age Distribution↗
PubMed1996

Breast cancer survival rates with mammographic screening: similar favorable survival rates for women younger and those older than 50 years.

PURPOSE: To evaluate the effect of a population-based mammographic screening program on breast cancer survival rates in women younger and in those older than 50 years of age. MATERIALS AND METHODS: A total of 56,881 women, aged 39-71 years, were invited to participate in mammographic screening one to four times during a 6 1/2-year period. RESULTS: A total of 671 cases of primary breast cancer were diagnosed, of which 472 (70%) cases were detected at screening. There was no substantial difference in stage distribution between women younger and those older than 50 years of age. The cumulative breast cancer survival rate for all women with breast cancer was 88% after 7 years; the cumulative breast cancer survival rates in women younger and in those older than 50 years of age were 92% and 87%, respectively. CONCLUSION: The similar breast cancer survival rates in women younger and in those older than 50 years suggest that mammographic screening can be effective in women aged 40-49 years.

Adult↗
PubMed2003

On crude and age-adjusted relative survival rates.

Relative survival rates, such as 5- or 10-year relative survival rates, which quantify "net survival" of cancer patients, are the most commonly reported measures of cancer outcome by cancer registries. Because relative survival rates vary with age for many forms of cancer, and because the age distribution of cancer patients varies between different populations or within one population over time, age adjustment of relative survival rates is often employed in international comparisons or in time series analyses of cancer patient survival. In this article, we show that derivation of crude and of age-adjusted relative survival rates in the traditional way is conceptually inconsistent, and that this inconsistency has important practical implications. We show ways to overcome this inconsistency in the derivation and interpretation of crude and age-adjusted relative survival rates.

Adolescent↗
PubMed1985

[A statistical study on the survival rate].

The survival rate is used as a criterion in evaluation of cancer treatment. This paper describes several view of various calculating methods for the survival rate by using a computer filing system of patients' records of cancer therapy as follow; Crude survival rate should not be used in usual follow-up study, if possible, because different results obtained from different determination for right censored cases. In case of value of the life table method or relative survival rate changed in short terms, re-computation by the more short interval (for example, from yearly monthly) must be analyzed for the reason of the quick exchange. According with improvement of the survival rate of cancer therapy, it is important to remark for the complication of normal tissues by radiation therapy at the end of treatment and during follow-up observation. Therefore, we proposed a new concept which is named "Cumulative effective survival rate" and is calculated by multiplying the average of cumulative weighted factors of complications of various normal tissues to the relative survival rate.

Actuarial Analysis↗
PubMed1982

Comparison of 5- and 10-year survival rates in operated gastric cancer patients. Assessment of the 5-year survival rate as a valid indicator of postoperative curability.

To evaluate whether it is appropriate to estimate the postoperative curability of gastric cancer based on the 5-year survival rate, we compared 5- and 10-year survival rates in 477 primary gastric cancer patients who had undergone gastrectomy during the 8-year period from 1960-1967. In patients who had died more than 5 years after surgery, the cause of death was investigated. The 10-year survival rate of 315 curatively operated patients was 59.1%, 2.9% lower than the 5-year survival rate. Of 176 patients who survived more than 5 years postoperatively, only 9 (5.1%) died of cancer recurrence, suggesting that the 5-year survival rate adequately reflects the curative success of gastric cancer surgery. The postoperative curability of gastric cancer is usually estimated by the 5-year survival rate. However, even in patients who survived for more than 5 years postoperatively, cancer recurrence has been observed. Therefore, we deemed it useful to assess whether it is appropriate to estimate the postoperative curability of gastric cancer based on the 5-year survival rate. From this point of view, we compared the 5- and 10-year survival rates of operated primary gastric patients and investigated the cause of death in patients who died more than 5 years postoperatively. Furthermore, in patients with cancer recurrence more than 5 years postoperatively, the pathologic findings on the cancer in the originally resected specimen were re-evaluated.

Adult↗
PubMed1977

The influence of presensitization on graft survival rate.

Graft survival rate was evaluated in 61 recipients with greater than 50 percent frequency of performed antibodies to selected panel cells. This includes recipients of primary cadaver grafts, secondary cadaver grafts, and living related grafts. Graft survival rate also was evaluated in 199 recipients with pretransplant antibodies reacting with 10 to 50 percent of panel cells and in nonsensitized patients. The results show that good graft survival can be obtained in many hyperimmunized patients, particularly in recipients of primary renal allografts (66 percent cadaver graft survival rate at 2 years). However, sensitization following rejection of an allograft appears to confer a less favorable prognosis. The nature of recipient presensitization and the precise specificity of each reactivity cannot always be explained. This is exemplified in three patients in whom broadly reactive lymphocytotoxic antibodies were not directed against HL-A antigens. Since the number of sensitized patients who await renal transplantation is increasing, there should be no hesitation in proceeding with transplantation, particularly with primary grafts. Emphasis, however, must be placed on frequent prospective recipient serum sampling so that transient high levels of cytotoxins do not escape detection and therefore can be easily selected out for cross-matching against potential donors.

Antibodies↗
PubMed1986

Recent trends in incidence and mortality rates for leukemias, and in survival rates for childhood acute lymphocytic leukemia, in Upstate New York.

Analysis of mortality rates for all childhood (age less than 20 years) leukemias in upstate New York showed declines between 1969-1971 and 1978-1980 for ages 0-4 and 5-9 years, while data from a population-based cancer registry for a population of about 10.5 million indicated no decline in incidence rates. Survival rates were examined for 552 children diagnosed with acute lymphocytic leukemia (ALL) in 1973-1980 at less than 15 years of age. There was some evidence for improvement in survival rates over these years of diagnosis, especially among children diagnosed at ages 1-4 and 10-14 years. Hazard rates increased among cases (especially males) diagnosed in 1979 and 1980, however, and this finding requires confirmation from other studies; the possible effect of influenza epidemics also should be explored. Only one confirmed second primary cancer, a rhabdomyosarcoma of the eye, was ascertained (as of the end of 1983), but longer follow-up is needed on children with ALL.

Adolescent↗
PubMedDate not supplied

[The correlation between the clinical stage and multimodal treatment in breast cancer expressed in the 5-year survival rate].

The survival rate in 143 patients with breast cancer followed up for 60 months has been evaluated by the regression Cox method and life table method, a number of representative variables for tumor and/or host being taken into account. The Cox model coefficients pointed out the following factors to positively influence the survival: age, premenopausal status, surgery, radiotherapy and complete chemotherapy (6-12 cycles). Negative and highly negative values recorded within variables: tumor over 5 cm, the presence of metastases, Karnofsky index less than 80 and the postmenopausal status generally correlated with the disease in advanced clinical stages. An apparently better survival in patients who underwent radiotherapy as compared to those who underwent an associated radiochemotherapy could be the result of the preferential associated treatment in advanced stages. The optimal intensity of chemotherapy positively influences the survival, except in late stages, suggesting the necessity of chemotherapy in initial stages.

Age Factors↗
PubMed2001

Targeted transarterial oily chemoembolization for small foci of hepatocellular carcinoma using a unified helical CT and angiography system: analysis of factors affecting local recurrence and survival rates.

OBJECTIVE: We assessed the local recurrence rate after a single targeted transarterial oily chemoembolization for small hepatocellular carcinoma with the unified helical CT and angiography system and analyzed the factors affecting the local recurrence rate and survival rate with Cox proportional hazards model. MATERIALS AND METHODS: For 54 consecutive patients with 71 small hepatocellular carcinomas (< or = 5 cm) with no more than two associated lesions, targeted oily chemoembolization was performed with an emulsion of doxorubicin hydrochloride mixed with iodized oil or a suspension of zinostatin stimalamer followed by gelatin sponge particles. When local recurrence or a new lesion appeared, follow-up targeted oily chemoembolization was performed. RESULTS: For 52 of 71 lesions, the catheterization to a subsegmental or more distal feeding artery could be performed. Local recurrence was recognized in 33.2% at 1 year and 37.8% at 2 and 3 years. The significant factors that affected local recurrence were tumor size (p = 0.005) and degree of deposition of iodized oil within the lesion (p = 0.049). The survival rates at 1, 2, and 3 years were 93.3%, 77.1%, and 77.1%, respectively. The significant factors affecting survival rate were tumor thrombus in large vessels (p = 0.0001), appearing after the first chemoembolization, and maximum tumor size (p = 0.022). CONCLUSION: Single targeted transarterial oily chemoembolization with the unified helical CT and angiography system had a low local recurrence rate for small hepatocellular carcinoma, and follow-up embolization resulted in a good survival rate. Tumor size along with degree of intratumoral iodized oil deposition and tumor thrombus along with maximum tumor size were significant factors affecting local recurrence and survival rate, respectively.

Aged↗
PubMed1983

[Survival rate of drug addicts. Longitudinal analysis of 530 outpatient clients for the admissions years 1969 to 1977].

The mortality amongst 530 out-patient drug-addicts, dependent mainly on opiates and being first registered between 1969 and 1977, was analysed. This grand total (27% females, median age 19 years, 73% males, median age 20 years) was subdivided into three groups with variable observation follow-up according to the time-shift of consumed main drugs. Until the demarcation day 31 December 1982 81 clients (15%) died. Mortality rates were determined according to the death cases for the three groups. In comparison with the mortality of the age-matched whole population male heroin addicts had a twelve-fold and females a 29-fold death rate. Survival curves of all three groups showed a rather linear course indicating a surprisingly long period of danger. For optimisation of advice methods and for treatment of drug-addicts long-term analyses of larger unselected groups involving further parameters are required.

Adolescent↗
PubMed1990

[New combined therapy of radiation and local administration of OK-432 for esophageal cancer--local control rate and two-year survival rate].

We devised new combination therapy of radiation and local administration of OK-432 and performed for 26 patients with esophageal cancer between March, 1987 and December, 1988 as a pilot study. The average age was 73 years. Among 26 patients, male were 20 and female were six. Patients were irradiated at the schedule of under 2 Gy/day and the dose of TDF (time, dose and fractionation factor) 100 totally. OK-432, 10KE was endoscopically administered around cancer lesion at the beginning of the radiotherapy, and two weeks later, 5KE was given in the same manner. Complete response was obtained 20 out of 26 cases (77%) and partial response was obtained in the remaining six cases (23%). All six patients with tumor length less than five cm showed complete response. All 16 patients who could not eat food orally before treatment, became to take food enough orally after the treatment and could discharge in good condition. One year and two years survival rate of 26 patients by Kaplan Meier method were 67.4% and 47.2%, respectively. Six patients with tumor length less than five cm, are all alive without a sign of recurrence. This combination therapy will improve not only the response rate and the survival rate, but also the quality of life of patients with esophageal cancer.

Aged↗